|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
AZD4547 results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:26853465 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt1s1 |
AKT1 substrate 1 |
decreases phosphorylation |
ISO |
AZD4547 results in decreased phosphorylation of AKT1S1 protein |
CTD |
PMID:26853465 |
|
NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677
|
|
G |
Frs2 |
fibroblast growth factor receptor substrate 2 |
increases phosphorylation |
ISO |
AZD4547 results in increased phosphorylation of FRS2 protein |
CTD |
PMID:26853465 |
|
NCBI chr 7:52,711,255...52,792,758
Ensembl chr 7:52,711,257...52,792,743
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
affects expression multiple interactions |
ISO |
AZD4547 affects the expression of MAP1LC3B protein modified form bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form] |
CTD |
PMID:26853465 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
AZD4547 results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:26853465 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
AZD4547 results in decreased expression of SREBF1 protein |
CTD |
PMID:26853465 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
affects expression |
EXP |
lenvatinib affects the expression of ATP5F1A protein |
CTD |
PMID:34019861 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Cat |
catalase |
decreases expression |
EXP |
lenvatinib results in decreased expression of CAT mRNA |
CTD |
PMID:34019861 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
affects expression |
EXP |
lenvatinib affects the expression of CDKN1A protein |
CTD |
PMID:34019861 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression |
EXP |
lenvatinib results in decreased expression of CPT1A mRNA |
CTD |
PMID:35788046 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
decreases expression |
EXP ISO |
lenvatinib results in decreased expression of CPT1B mRNA; lenvatinib results in decreased expression of CPT1B protein |
CTD |
PMID:35788046 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
EXP ISO |
lenvatinib results in decreased expression of CPT2 mRNA; lenvatinib results in decreased expression of CPT2 protein |
CTD |
PMID:35788046 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Dnm1l |
dynamin 1-like |
increases expression |
EXP |
lenvatinib results in increased expression of DNM1L mRNA |
CTD |
PMID:34019861 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Fis1 |
fission, mitochondrial 1 |
increases expression |
EXP |
lenvatinib results in increased expression of FIS1 mRNA |
CTD |
PMID:34019861 |
|
NCBI chr12:19,708,558...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Lonp1 |
lon peptidase 1, mitochondrial |
decreases expression |
EXP |
lenvatinib results in decreased expression of LONP1 protein |
CTD |
PMID:34019861 |
|
NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
increases expression |
EXP |
lenvatinib results in increased expression of MAP3K5 mRNA |
CTD |
PMID:34019861 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression |
EXP |
lenvatinib results in increased expression of MAPK8 mRNA |
CTD |
PMID:34019861 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mfn1 |
mitofusin 1 |
affects expression |
EXP |
lenvatinib affects the expression of MFN1 mRNA |
CTD |
PMID:34019861 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mfn2 |
mitofusin 2 |
affects expression |
EXP |
lenvatinib affects the expression of MFN2 mRNA |
CTD |
PMID:34019861 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
affects expression decreases expression |
EXP |
lenvatinib affects the expression of COX1 protein lenvatinib results in decreased expression of COX1 protein |
CTD |
PMID:34019861 PMID:35788046 |
|
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Ndufb8 |
NADH:ubiquinone oxidoreductase subunit B8 |
affects expression |
EXP |
lenvatinib affects the expression of NDUFB8 protein |
CTD |
PMID:34019861 |
|
NCBI chr 1:243,408,659...243,413,701
Ensembl chr 1:243,408,619...243,413,817
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression |
EXP |
lenvatinib results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:34019861 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
affects expression |
EXP |
lenvatinib affects the expression of NRF1 mRNA |
CTD |
PMID:34019861 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
increases expression |
EXP |
lenvatinib results in increased expression of OPA1 mRNA |
CTD |
PMID:34019861 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Sdhb |
succinate dehydrogenase complex iron sulfur subunit B |
decreases expression |
EXP |
lenvatinib results in decreased expression of SDHB protein |
CTD |
PMID:34019861 PMID:35788046 |
|
NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
decreases expression |
ISO EXP |
lenvatinib results in decreased expression of SLC22A5 protein lenvatinib results in decreased expression of SLC22A5 mRNA; lenvatinib results in decreased expression of SLC22A5 protein |
CTD |
PMID:35788046 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc25a20 |
solute carrier family 25 member 20 |
decreases expression |
ISO EXP |
lenvatinib results in decreased expression of SLC25A20 protein lenvatinib results in decreased expression of SLC25A20 mRNA; lenvatinib results in decreased expression of SLC25A20 protein |
CTD |
PMID:35788046 |
|
NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
EXP |
lenvatinib results in increased expression of SOD2 mRNA |
CTD |
PMID:34019861 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression |
EXP |
lenvatinib results in decreased expression of UCP2 mRNA; lenvatinib results in decreased expression of UCP2 protein |
CTD |
PMID:34019861 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Uqcrc2 |
ubiquinol cytochrome c reductase core protein 2 |
affects expression decreases expression |
EXP |
lenvatinib affects the expression of UQCRC2 protein lenvatinib results in decreased expression of UQCRC2 protein |
CTD |
PMID:34019861 PMID:35788046 |
|
NCBI chr 1:175,167,933...175,198,499
Ensembl chr 1:175,167,894...175,199,453
|
|
|
G |
Tuba1a |
tubulin, alpha 1A |
decreases expression |
ISO |
nintedanib results in decreased expression of TUBA1A mRNA |
CTD |
PMID:27015953 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of BIRC5 protein |
CTD |
PMID:27794399 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[PKI 166 co-treated with PD 173074] results in decreased expression of CCND1 protein |
CTD |
PMID:15377668 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
ISO |
PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] |
CTD |
PMID:15709206 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases activity decreases expression multiple interactions |
ISO |
PD 173074 results in decreased activity of FGFR1 protein PD 173074 results in decreased expression of FGFR1 protein [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Arsenic Trioxide promotes the reaction [PD 173074 results in decreased expression of FGFR1 protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of FGFR1 protein] |
CTD |
PMID:22683780 PMID:27794399 |
|
NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
decreases activity |
ISO |
PD 173074 results in decreased activity of FGFR3 protein |
CTD |
PMID:15029211 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
multiple interactions decreases activity |
ISO |
PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] PD 173074 results in decreased activity of FGFR4 protein |
CTD |
PMID:15377668 PMID:15709206 |
|
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] |
CTD |
PMID:22683780 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation decreases expression multiple interactions |
ISO |
PD 173074 results in decreased phosphorylation of MAPK1 protein PD 173074 results in decreased expression of MAPK1 protein PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15029211 PMID:25953896 PMID:27794399 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation decreases expression multiple interactions |
ISO |
PD 173074 results in decreased phosphorylation of MAPK3 protein PD 173074 results in decreased expression of MAPK3 protein PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15029211 PMID:25953896 PMID:27794399 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions |
ISO |
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] |
CTD |
PMID:22683780 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with PD 173074] results in increased expression of PARP1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in increased expression of PARP1 protein modified form; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in increased expression of PARP1 protein modified form |
CTD |
PMID:27794399 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Phlpp1 |
PH domain and leucine rich repeat protein phosphatase 1 |
multiple interactions |
ISO |
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]; PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:25953896 |
|
NCBI chr13:22,308,532...22,530,978
Ensembl chr13:22,308,548...22,530,977
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
decreases expression multiple interactions |
ISO |
PD 173074 results in decreased expression of RAF1 protein; PD 173074 results in decreased expression of RAF1 protein modified form [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein; [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein modified form; arsenic trioxide promotes the reaction [PD 173074 results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein] |
CTD |
PMID:27794399 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[PKI 166 co-treated with PD 173074] results in decreased activity of RPS6KB1 protein |
CTD |
PMID:15377668 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions decreases expression |
ISO |
[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in decreased expression of SRC protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of SRC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein modified form]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein] PD 173074 results in decreased expression of SRC protein; PD 173074 results in decreased expression of SRC protein modified form |
CTD |
PMID:27794399 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Tbx3 |
T-box transcription factor 3 |
multiple interactions |
ISO |
PD 173074 inhibits the reaction [afimoxifene results in increased expression of TBX3 protein]; PD 173074 inhibits the reaction [Estrogens results in increased expression of TBX3 protein] |
CTD |
PMID:21098263 |
|
NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]]; PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA] |
CTD |
PMID:26800359 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|